Allogene Therapeutics, Inc. (ALLO) Stock Price & Analysis
Allogene Therapeutics, Inc. (ALLO) fell 0.51% to USD 1.97 as of September 8, 2026 at 05:43 UTC, according to Nexqual real-time market data.
ALLO last closed at USD 1.98; the session ranged USD 1.95–2.01 on volume of 4,428,567 shares. Market capitalization is $680.62M, with a 52-week range of USD 1.04–4.46 (NMS). Source: Nexqual, September 8, 2026 at 05:43 UTC.
Key Statistics (as of September 8, 2026 at 05:43 UTC)
| Price | USD 1.97 |
|---|---|
| Change | ▼ 0.51% (down) |
| Previous Close | USD 1.98 |
| Open | USD 1.95 |
| Day Range | USD 1.95 – 2.01 |
| 52-Week Range | USD 1.04 – 4.46 |
| Volume | 4,428,567 shares |
| Market Cap | $680.62M |
| Exchange | NMS |
Technical Analysis (ALLO)
Nexqual's technical model rates ALLO "SELL" based on 2 bullish and 4 bearish signals across 128 daily candles, as of September 8, 2026 at 05:43 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 48.12 (neutral) |
| vs SMA50 | Below (USD 1.98) |
| MACD | 0 (positive) |
Analyst Ratings (ALLO)
Wall Street analysts rate ALLO "Strong Buy" based on 9 analysts, with a mean price target of USD 9 (range USD 4–14), per Nexqual as of September 8, 2026 at 05:43 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 9 |
| Mean Target | USD 9 |
| High Target | USD 14 |
| Low Target | USD 4 |
| Buy / Hold / Sell | 11 / 1 / 0 |
Earnings (ALLO)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD -0.14 |
| Revenue Estimate | $2,000 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.13 vs est -0.15 ▲ beat |
| 2026-03-31 | USD -0.18 vs est -0.18 ▲ beat |
| 2025-12-31 | USD -0.17 vs est -0.22 ▲ beat |
| 2025-09-30 | USD -0.19 vs est -0.23 ▲ beat |
Source: Nexqual, September 8, 2026 at 05:43 UTC.
Financials & Fundamentals (ALLO)
| Total Revenue | $4.64M |
|---|---|
| Gross Margin | +0.00% |
| Operating Margin | -1011.21% |
| Profit Margin | +0.00% |
| ROE | -42.39% |
| Debt / Equity | 18.11 |
| Current Ratio | 10.72 |
| Total Cash | $332.60M |
| Total Debt | $79.01M |
| Free Cash Flow | $-63.46M |
Source: Nexqual, September 8, 2026 at 05:43 UTC.
Financial Health Score (ALLO)
Nexqual rates Allogene Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of September 8, 2026 at 05:43 UTC.
| Growth | Critical — Revenue -100% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $333M cash vs $79M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$102M |
| Efficiency | Critical — ROE -42%, ROA -22.1% |
Ownership (ALLO)
| Insider Ownership | +11.03% |
|---|---|
| Institutional Ownership | +87.61% |
| Shares Outstanding | 345.49M |
| Float | 262.41M |
| Short % of Float | +18.88% |
Source: Nexqual, September 8, 2026 at 05:43 UTC.
Leadership (ALLO)
Allogene Therapeutics, Inc. is led by Zachary J. Roberts (age 47), President, CEO & Director, per Nexqual as of September 8, 2026 at 05:43 UTC.
| President, CEO & Director | Zachary J. Roberts (age 47) |
|---|---|
| Co-Founder & Executive Chairman | Arie S. Belldegrun F.A.C.S. (age 76) |
| Co-Founder & Director | Joshua A. Kazam (age 48) |
| Co-Founder & Director | David D. Chang (age 65) |
| Executive VP & CFO | Geoffrey M. Parker (age 60) |
Major Backers & Investors (ALLO)
Notable institutional backers of Allogene Therapeutics, Inc. include Frazier Life Sciences Management, L.P. , Pfizer Inc, TPG GP A, LLC, according to Nexqual as of September 8, 2026 at 05:43 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Frazier Life Sciences Management, L.P. | 6.5% |
| Pfizer Inc | 6.38% |
| TPG GP A, LLC | 5.42% |
| Sio Capital Management, LLC | 3.86% |
| Fidelity | 3.83% |
| Primecap Management Company | 3.8% |
| FMR, LLC | 3.48% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 10.73% |
| Vanguard Group | 9.68% |
| State Street | 9.02% |
Source: Nexqual, September 8, 2026 at 05:43 UTC.
From Allogene Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-12)
Key Strengths & Strategy (as disclosed to the SEC)
- Multiple autologous anti-CD19 CAR T therapies have shown promising results and have been approved by the FDA as therapies in multiple blood cancers, including relapsed/refractory (R/R) LBCL, as further described below under "—Competition".
- This practice encompasses a wide range of indications and modalities, including those classified as Advanced Therapy Medicinal Products by the EMA.
- We believe a critical component to our success will be to leverage and expand our proprietary manufacturing know-how, expertise and capacity.
- Product Pipeline and Development Strategy Using our proprietary allogeneic CAR T cell platform, we are researching and developing multiple product candidates for the treatment of blood cancers, solid tumors and autoimmune diseases.
Partnerships
- In February 2025, we entered into an Amended and Restated Strategic Collaboration Agreement with Foresight Diagnostics which expands our collaboration to enable the development of Foresight Diagnostics' CLARITY TM MRD assay as a companion diagnostic in the EU, UK, Canada and Australia in support of Allogene's clinical development of cema-cel.
- On May 10, 2024, we entered into an Amendment and Settlement Agreement (the Servier Amendment) with Servier which restructures our relationship under the Servier Agreement.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ATRA | Atara Biotherapeutics, Inc. | USD 9.76 | ▲ 3.39% |
| FATE | Fate Therapeutics, Inc. | USD 2.48 | ▲ 1.22% |
| AUTL | Autolus Therapeutics plc | USD 2.24 | ▲ 0% |
| DNLI | Denali Therapeutics Inc. | USD 22.28 | ▼ 2.49% |
| ARVN | Arvinas, Inc. | USD 9.39 | ▼ 2.09% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 05:43 UTC. This page is informational and not investment advice.